Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would drugmakers agree to reduce their prices right away?

Losing weight in the new year won't take the same shape as it did in the past. Why it matters: The emergence of groundbreaking new weight-loss drugs is transforming how Americans shed pounds. Nearly 18 million Americans are expected to be taking versions of GLP-1 drugs by 2029,

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s SC Johnson College of Business and consumer data firm Numerator.

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, a recent study based on data from the market research firm Numerator indicates.